As we move into Q2, the team at Bluewell Peptides is pleased to share several developments reflecting our long-term commitment to supporting laboratory research with reliable supply, clear documentation, and consistent quality-control processes.
Over the past months, we have been working behind the scenes to expand our catalogue, improve our operational infrastructure, and strengthen the standards that support the Bluewell research range.
This update outlines what researchers can expect in the coming months.
New Research Peptides Being Added to the Catalogue
One of the developments heading into Q2 is the expansion of our research peptide catalogue.
These additions are currently listed in our Coming Soon section and will become available as stock arrives and the relevant quality-control processes are completed.
Upcoming additions include:
- AICAR 50mg
- BPC-157 + TB-500 Blend 20mg
- Dermorphin 5mg
- FTTP Adipotide 5mg
- Hexarelin Acetate 5mg
- Pinealon 20mg
- PNC-27 5mg
- Thymalin 10mg
- VIP 10mg
Relevant products will continue to follow the Bluewell quality-control framework, including where applicable:
- HPLC analytical testing
- Certificates of Analysis
- Appropriate storage conditions
- Batch identification and traceability
These compounds are associated with a range of areas of scientific interest, including cellular signalling, neuropeptide pathways, metabolic research, and peptide-related biological systems.
Our aim is to continue expanding the catalogue with compounds relevant to modern laboratory research while maintaining clear documentation and consistent quality standards.
For Research Use Only. Not for Human or Veterinary Use.
Expansion to a New Shipping and Fulfilment Facility
Another important development for Bluewell this quarter is our move to a new dedicated shipping and fulfilment facility.
As order volumes and catalogue size have increased, expanding our operational capacity allows us to maintain organised storage, inventory control, and reliable fulfilment.
During the transition, some compounds may temporarily appear as out of stock while new batches are transferred, documented, and incorporated into the updated inventory system.
Normal availability is expected to return as the transition is completed.
The new facility provides:
- Increased storage capacity
- Dedicated temperature-controlled storage
- Improved order-processing and dispatch workflows
- More efficient inventory-management systems
This upgrade is designed to support reliable UK and international fulfilment as the Bluewell research catalogue expands.
Growing the Bluewell Team
Alongside the facility expansion, we are also expanding our operational team.
Additional staff are being introduced to support areas including fulfilment, documentation, quality-control administration, and customer service.
Our focus is on sustainable growth that maintains precision, reliability, and transparency across the business.
This includes additional support for:
- Order processing
- Quality-control workflows
- Research documentation
- Customer support
- Inventory and fulfilment operations
Strengthening Quality-Control Processes
Quality control remains an important part of how Bluewell operates.
As part of our Q2 expansion, we are continuing to improve our internal quality-control procedures and the way analytical documentation is managed across product batches.
These improvements are intended to strengthen batch traceability, documentation, and consistency across the research materials we supply.
Where analytical testing is conducted by external laboratories, relevant documentation is retained and made available where applicable.
Introducing Additional Endotoxin Testing
As part of the developing quality-control framework, Bluewell is introducing additional endotoxin testing for selected research materials where appropriate.
This provides researchers with further analytical information alongside existing quality documentation.
Testing requirements may vary depending on the individual compound, batch, and intended laboratory research context.
Where endotoxin testing is performed, the relevant results will be documented alongside the associated batch information.
Raising Standards for Research Suppliers
The research peptide sector has expanded considerably, and supplier standards can vary.
At Bluewell Peptides, our aim is to maintain a research-focused supply model centred around:
- Clear documentation
- Analytical testing
- Batch traceability
- Transparent product information
- Appropriate storage
- Reliable fulfilment
- Ongoing quality-control improvements
We believe researchers should have access to clear information about the materials incorporated into laboratory work.
Looking Ahead
Q2 represents another stage in the continued development of Bluewell Peptides.
With an expanding catalogue, increased fulfilment capacity, and strengthened quality-control systems, our focus remains on building a reliable platform for laboratory researchers.
The coming months will include:
- New research peptides added to the catalogue
- Improved fulfilment capabilities
- Strengthened quality-verification processes
- Continued investment in storage, documentation, and operational infrastructure
We appreciate the continued support of researchers and laboratories using Bluewell as a supplier of research materials.
For Research Use Only. Not for Human or Veterinary Use.



